RxDoctor Payments Data

Jude Agendia, MD

Family Medicine · Lake Charles, LANPI 1821287806

Payments from drug & device makers

$1,607in general payments, 2019–2025

Across 44 payments — averaging $36.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$354
  • Amgen$286
  • Idorsia Pharmaceuticals US Inc$153
  • Medtronic$130
  • Biohaven Pharmaceuticals, Inc.$125
  • Esperion Therapeutics, Inc.$105
  • plus $454 from 9 others

What the payments were for

  • Food & beverage$1,607100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,607 in reported general payments places this provider in the 60th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$126,341
Medicare patients
368
Services billed
1,293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide85$112,519
MounjaroTirzepatide52$57,666
EliquisApixaban41$35,054
LinzessLinaclotide38$30,768
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$15,347
MyrbetriqMirabegron22$13,518
JardianceEmpagliflozin11$11,356
Praluent PenAlirocumab19$9,094
Atrovent HfaIpratropium Bromide11$4,884
SymbicortBudesonide/Formoterol Fumarate20$4,201
Albuterol Sulfate HfaAlbuterol Sulfate134$4,014
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$3,115
Venlafaxine Hcl ErVenlafaxine Hcl39$2,908
Gabapentin154$2,210
Novolog FlexpenInsulin Aspart14$1,681

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$50$112,51985 claims
Lilly USA, LLCMounjaro$33$57,66652 claims
PfizerEliquis$96$35,05441 claims
AbbVieLinzess$354$30,76838 claims
Astellas Pharma US IncMyrbetriq$51$13,51822 claims
AstraZenecaSymbicort$53$4,20120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Lake Charles

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →